Skip to main content
OpenTrials
Completed

NCT Number: NCT05902117

Place of Copeptin-troponin Assay in the Elimination Diagnosis of Non-ST+ ACS

The aim of this study is to demonstrate that a combined troponin and copeptin assay can exclude non-ST+ ACS in patients with chest pain less than 6 hours old.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Emergency Department (SAMU) Hospital NOVO - Pontoise site, Pontoise, France

Loading trial locations.

About this study

Chest pain accounts for about 10% of emergency service visits, which represents between 6 and 8 million visits per year in the United States and 15 million in Europe. Depending on the series, coronary etiology is found in 10 to 50% of cases.

Two types of coronary syndrome are distinguished according to the existence of a pathological change in the electrocardiogram.

ST+ acute coronary syndrome is a diagnosis based on the association of chest pain associated with an electrocardiogram change in the form of ST-segment elevation in a systemic territory corresponding to the complete obstruction of an artery of the coronary network.

Non-ST+ coronary syndrome is more difficult to diagnose, as the ECG is not pathological or cannot be interpreted due to the presence of conduction disorders. The diagnosis is currently based on the pathological increase of a specific myocardial biomarker in the blood: troponin.

If the pain is recent (less than six hours) the troponin measured on arrival may be falsely negative, and therefore requires a second measurement 3 hours after the first one (this is the troponin cycle). This second test therefore leads to a longer stay for patients requiring it and contributes to the saturation of the emergency service.

Copeptin is an endogenous stress biomarker that rises immediately during a myocardial infarction and decreases rapidly. Unlike troponin, this marker is not myocardial specific and its level can rise in the blood for many reasons, which is why this marker cannot be used alone in the diagnosis of non-ST+ acute coronary syndrome (non-ST+ ACS or ST- ACS).

The hypothesis would be that the association of a copeptin assay with the initial troponin assay could, if both markers are below pathological thresholds (Troponin < 16ng.dL), eliminate the diagnosis of acute coronary syndrome from the first assays and thus avoid the second troponin assay 3 hours after the first. The patient would reduce the time spent in the emergency and would thus reduce the number of patients in the emergency service.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient ≥18 years old
  • Presenting at the Pontoise emergency department by their own means / ambulance or patients taken care of by the SMUR and referred to the NOVO hospital - Pontoise site
  • Chest pain less than 6 hours old
  • Chest pain suggestive of ACS (compressive, intense pain, radiating into the arm and neck, mid-thoracic, left thoracic or epigastric location)
  • Non-contributory ECG (no ST elevation, presence of bundle branch block)
  • Informed and having expressed no objection
  • Beneficiary of a social security system (or entitled person)

Non -Inclusion Criteria:

  • Sus ST-segment shift on ECG (ACS ST+)
  • Intermittent pain/unclear onset time
  • Pregnant woman
  • Pain in the context of trauma
  • Patient under guardianship
  • Patient does not speak or understand French

Exclusion criteria

  • Non-ultrasensitive troponin measurement positive during the 1st SMUR sampling (> 0.08 ng.dL)
  • Patient not referred to the NOVO hospital - Pontoise site by the SMUR

Treatment and study plan

Troponin and Copeptin assay

Diagnostic Test

Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.

Primary outcomes

  1. Demonstrate that a combined troponin and copeptin assay can exclude non-ST+ ACS in patients with chest pain less than 6 hours old (sensitivity/specificity)

    Time frame: At the end of the study, an average of 8 month

    Comparison of copeptin and troponin assays in the final diagnosis of non-ST+ ACS based on emergency medical records by calculation the sensitivity/specificity of the troponin - copeptin pair.

  2. Demonstrate that a combined troponin and copeptin assay can exclude non-ST+ ACS in patients with chest pain less than 6 hours old (negative predictive value)

    Time frame: At the end of the study, an average of 8 month

    Comparison of copeptin and troponin assays in the final diagnosis of non-ST+ ACS based on emergency medical records by calculation of the negative predictive value of the troponin - copeptin pair.

Secondary outcomes

  1. Evaluation of the diagnostic performance (sensitivity/specificity) of the troponin/ copeptin association according to cardiovascular risk factors (age, smoking, hypertension, history of cardiac ischemia, overweight, heredity)

    Time frame: At the end of the study, an average of 8 month

    Evaluation of the diagnostic performance (sensitivity/specificity) of the troponin - copeptin pair for each subgroup of cardiovascular risk factors (age / smoking / hypertension / history of cardiac ischemia / overweight and heredity).

  2. Evaluation of the diagnostic performance (negative predictive value) of the troponin/ copeptin association according to cardiovascular risk factors (age, smoking, hypertension, history of cardiac ischemia, overweight, heredity)

    Time frame: At the end of the study, an average of 8 month

    Evaluation of the diagnostic performance (negative predictive value) of the troponin - copeptin pair for each subgroup of cardiovascular risk factors (age / smoking / hypertension / history of cardiac ischemia / overweight and heredity).

  3. Evaluation of the patient's length of stay

    Time frame: At the end of the Study, an average of 8 month

    Collection of the number of days or hours spent in the emergency service from the time of arrival

  4. Evaluation of the diagnostic performance of the troponin/ copeptin combination according to the time from onset of pain

    Time frame: At the end of the study, an average of 8 month

    The diagnostic performance of the troponin/ copeptin combination is evaluated according to the time between the first pain and blood sampling

  5. Evaluation of pain management in emergency service

    Time frame: At the end of the study, an average of 8 month

    Assessment of the evolution of pain via the numerical scale (EN), rated from 0 to 10, between arrival in the emergency room and reassessment at 3 hours

Sponsors and collaborators

Lead sponsor

Hôpital NOVO

Other

Registry information

Official study title

Place of Copeptin-troponin Assay in the Elimination Diagnosis of Non-ST+ ACS in the Management of Pre-hospital and In-hospital Non-traumatic Chest Pain in Adults

Acronym: CopSCA

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jun 13, 2023
Registry last updated
Mar 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.